A nonconservative leucine to proline mutation in peripheral myelin protein 22 (PMP22) causes the Trembler-J (Tr J ) neuropathy in mice and humans. The expression levels and localization of the PMP22 protein in the Tr J mouse have not been previously determined. The aim of our studies was to reevaluate the extent of myelin deficit in genotyped heterozygous and homozygous animals and to examine how the Tr J mutation alters the normal in vivo post-translational processing of PMP22. Morphological studies show evidence for primary dysmyelination and myelin instability in affected animals. As expected, Western blot analysis indicates that in adult heterozygous Tr J animals, the level of PMP22 is markedly decreased, similar to myelin basic protein and protein zero, whereas myelin-associated glycoprotein is largely unaffected. The decrease in myelin protein expression is associated with an increase in lysosomal biogenesis, suggestive of augmented endocytosis or autophagy. Double-immunolabeling experiments show the accumulation of PMP22 in endosomal/lysosomal structures of Tr J Schwann cells, and chloroquine treatment of nerve segments indicates that the degradation of protein zero, PMP22, and myelin basic protein is augmented in Tr J nerves. These studies suggest that the Tr J mutation alters myelin stability and that the mutant protein is likely degraded via the lysosomal pathway.
MATERIALS AND METHODS

Heterozygous Tr
J animals in the C57BL/6J background were obtained from Jackson Laboratories (Bar Harbor, ME) and were used to establish a breeding colony at Stanford University.
Genotyping. Genomic DNA was isolated from the tails of newborn mouse pups, and a 103 bp fragment of the pmp22 gene containing the mutated region was amplified using PCR (forward primer 5Ј-GAT-CCCGAGCCCAACTC, reverse primer 5Ј-CTGACGATGGTGGA-GAC). Reaction conditions were as follows: initial denaturation at 97°C for 1 min, followed by three cycles of 65°C for 1 min, 72°C for 40 sec, and 97°C for 30 sec. During a 4 min time delay period at 72°C, an additional 2.5 U of AmpliTaq DNA polymerase (Perkin-Elmer, Norwalk, CT) was added to each sample. Next, 30 cycles at 94°C for 30 sec, 60°C for 1 min, and 72°C for 40 sec, followed by a final extension at 72°C for 10 min, were completed in a Perkin-Elmer Cetus DNA Thermal Cycler. An aliquot of each PCR product was incubated with BanI restriction enzyme (New England Biolabs, Beverly, MA) for 90 min at 37°C. Control and enzymetreated samples were analyzed on 6% acrylamide gels using a standard Tris-borate-EDTA buffer system, and DNA bands were visualized by ethidium bromide staining.
Morphological studies. For the morphological studies, all reagents were obtained from Electron Microscopy Sciences (Fort Washington, PA). Sciatic nerves were collected from P10 and adult genotyped animals. Samples were fixed by immersion in ice-cold 2% glutaraldehyde/2% paraformaldehyde in 0.1 M sodium cacodylate buffer, pH 7.4, overnight at 4°C. After five 10 min rinses in PBS, nerves were infiltrated with 80 mM sucrose containing PBS and processed for standard Epon embedding. Plastic sections (0.5 mm) were stained with toluidine blue enhanced with silver. Measurements were performed on images captured with a Cohu CCD camera (Model 4915-4000) digitized through a Scion VG5 frame grabber onto a Macintosh computer running the public domain National Institutes of Health Image program (v1.59, available through the Internet at http://rsb.info.nih.gov/nih-image/, developed at NIH). Statistics were performed by two-tailed ANOVA using the SPSS software package.
Immunocytochemical studies. Sciatic nerves were dissected out from genotyped animals at P10, P18, and adult. Samples were frozen by immersion in freezing N-methyl butane (isopentane). Frozen sections (10 m thick) were dried for 1 hr on Superfrost/Plus microslides (Fisher, Pittsburgh, PA) followed by fixation with 1% paraformaldehyde in 90% ethanol for 2 min at room temperature. Samples were blocked by incubation in PBS containing 20% normal goat serum for at least 30 min. Primary antibodies (see below) were added in the same blocking solution overnight at 4°C. After four 10 min rinses in PBS, the sections were incubated with anti-rat IgG FITC conjugate (Boehringer Mannheim, Indianapolis, IN) or anti-rabbit IgG Texas red conjugate (Jackson ImmunoResearch Laboratories, West Grove, PA) for 1-2 hr. Hoechst dye #33258 (Polysciences, Warrington, PA) was included in the secondary antibody solution at 0.5 g /ml. Samples were mounted with Citifluor City, IA) at 12 g /ml and anti-lysosome associated membrane protein (LAMP1) (clone 1D4B, Developmental Studies Hybridoma Bank, Iowa City, IA) at 13 g /ml were used for the immunocytochemical studies.
Deglycosylation and Western analysis. Sciatic nerves were collected from genotyped 18-d-old and adult animals and were frozen immediately in liquid nitrogen. Nerves pooled from two to four animals were pulverized under liquid nitrogen, and total tissue homogenates were prepared in SDS gel sample buffer (62.5 mM Tris, pH 6.8, 10% glycerol, 3% SDS) or in denaturation buffer (0.5% SDS, 1% ␤-mercaptoethanol), supplied with the endoglycosidases, for the deglycosylation studies. Protein concentrations were determined using BCA reagents (Pierce Chemicals, Rockford, IL) or the Lowry method. Endoglycosidase digestions with N-glycosidase F (PNGase F) and endoglycosidase H (endoH), both from New England Biolabs, were performed according to the manufacturer's suggestions, for 16 hr at 37°C. Protein samples were separated on 12.5% SDS gels under reducing conditions, and gels were transferred to nitrocellulose membranes. The same polyclonal antibodies as above, anti-PMP22 at 1:1000, anti-MBP at 1:4000, anti-P0 at 1:4000, anti-MAG at 1:1000, and anti-cathepsin D (CatD), purified rabbit IgG (Cortex Biochem, San Leandro, CA) at 1:100, and rat monoclonal anti-LAMP1 undiluted supernatant were used. Bound antibodies were detected using the ECL chemiluminescent detection method (Amersham Corporation, Arlington Heights, IL).
Chloroquine treatment. To prevent lysosomal degradation, excised normal and Tr J sciatic nerves were incubated in DMEM, 10% fetal calf serum, and 100 ng/ml nerve growth factor, with and without the addition of 100 M chloroquine (Calbiochem, La Jolla, CA), overnight at 37°C. Samples were quickly frozen and processed for immunocytochemical studies and Western analysis as described above.
progressive. In agreement with the histological findings, ϩ/ϩ and Tr J /ϩ animals are behaviorally indistinguishable at young age (until 3-4 weeks of age), whereas Tr J /ϩ animals display noticeable tremors in adulthood. The neuropathy often progresses to complete paralysis of the hind legs in older animals. In comparison, Tr J /Tr J pups display tremors, problems with movements soon after birth (P5-P7), remain smaller in size, and generally die at ϳP18 -P22 (weaning age), possibly because of inability to obtain proper nutritional support.
Although the 10-d-old ϩ/ϩ and Tr J /ϩ nerves appear similar, there are significant differences between the ratios of the fiber (axon and myelin together) to axon diameters (referred as g ratios: ϩ/ϩ, 0.47 Ϯ 0.09; Tr J /ϩ, 0.55 Ϯ 0.11; p Ͻ 0.001, ratios calculated from all myelinated axons in representative fields on at least 50 fibers) (compare Fig. 2, A and B) . Because the overall axon diameters are similar between ϩ/ϩ and Tr J /ϩ animals at this age (average axon diameters: ϩ/ϩ, 1.41 Ϯ 0.49 m; Tr J /ϩ, 1.39 Ϯ 0.37 m), the differences in the g ratios indicate a significant decrease in the thickness of myelin in Tr and E, and 3). Taken together, these data suggest that the heterozygous Tr J phenotype is expressed during early myelin formation and appears more severe in older animals because of an arrest in the size of the axon-Schwann cell units. However, even when normalized for axon size, scatterplots demonstrate that axons from Tr J /ϩ mice have less myelin than littermate controls, at least for axon diameters Ͼ1 mm (Fig. 3 ).
PMP22 protein levels are reduced out of proportion to other myelin proteins in the Tr J neuropathy
The abnormally thin myelin observed in younger animals and the nonconservative nature of the Tr J mutation are consistent with the notion that the mutated allele either interferes with myelin formation or enhances myelin degradation through an intracellular mechanism. As a first step in evaluating the intracellular processing of PMP22, we performed immunoblots to compare the levels of PMP22 protein expression with those of other known peripheral myelin protein constituents. Accordingly, total sciatic nerve lysates of P18 and adult mice were analyzed for the expression of MAG, P0, MBP, and PMP22, as shown in Figure 4 . As expected from the pathology, severely affected Tr J /Tr J nerves contained nearly undetectable amounts of P0 and MBP and essentially no anti-PMP22 immunoreactive protein even when up to 100 g of nerve lysate protein was analyzed. In adult heterozygous animals, the levels of P0 and MBP, the major structural proteins of PNS myelin, were severely reduced. We found PMP22 protein levels similarly decreased. In comparison, we did not detect a significant alteration in the amount of MAG in Tr J /ϩ mice between P18 and adulthood. Similar to the Tr J /ϩ condition, MAG levels in Tr J /Tr J animals remained approximately normal; however, a low molecular weight form of the molecule, possibly resulting from altered glycosylation (Johnson et al., 1989 ; our unpublished observations), was also detected. We found no evidence of a higher molecular weight form of MAG in any of the nerve lysates, as has been described previously in Tr animals (Inuzuka et al., 1985) . The relative differences in P0 and MBP protein levels between the ϩ/ϩ and Tr J /ϩ animals are much less pronounced at P18. In contrast, PMP22 protein expression is apparently reduced in P18 heterozygotes compared with normals.
Most of the steady-state PMP22 protein undergoes complex glycosylation in heterozygous Tr J nerves
We investigated the acquisition of PMP22 glycosylation in Tr J /ϩ nerves to determine whether we could detect differences in the intracellular processing of the PMP22 protein in affected animals. Previous pulse-chase studies have demonstrated that PMP22 is synthesized as a core 18 kDa protein and then progressively modified by glycosylation to a 22 kDa high-mannose form (endoH-sensitive) and finally to a 22 kDa complex form (endoHresistant) (Pareek et al., 1993) . Thus, we compared the glycosylation profile of the protein in 18-d-old and adult normal and Tr J /ϩ mice (Fig. 5) as a marker for the extent of its intracellular processing through the Golgi network. As expected, PNGase F digestion revealed that the size of the core peptide is approximately the same in all samples (18 kDa). During normal peripheral nerve development, a greater fraction of the total PMP22 becomes endoH-resistant; however, a significant endoH-sensitive pool remains, even in normal adult nerves, probably representing an ER and /or Golgi pool of newly synthesized PMP22. At P18, the ratio of endoH-sensitive to endoH-resistant protein is similar in ϩ/ϩ and Tr J /ϩ nerves. In adult Tr J /ϩ nerves, however, PMP22 almost exclusively contains complex-type sugars. As a control, anti-P0 immunoblots of identical samples revealed a similar but less pronounced shift of the P0 protein toward complex glycosylation in adult Tr J /ϩ nerves (Fig. 5 ). This result is in agreement with the accumulation of P0 in Golgi-associated vesicles in Tr J /ϩ nerves (Heath et al., 1991) . Because of the low levels of PMP22 in Tr J /Tr J animals, similar Western blot studies on the carbohydrate content of the protein could not be performed. The lack of detectable levels of endoH sensitive PMP22 in adult Tr J /ϩ nerves suggests that at steady-state, most of PMP22 is transported and processed through the trans-Golgi network in Tr J /ϩ nerves without accumulating in the ER or the early Golgi network. However, these data alone do not rule out the possibility that the endoHresistant PMP22 represents only the product of the normal allele. To follow further the processing of PMP22 in Tr J /ϩ animals, we used immunostaining of frozen nerve sections with polyclonal anti-PMP22 antibodies. In the normal peripheral nerve, PMP22 is found distributed uniformly in compact myelin and is absent from the nodes of Ranvier (Fig. 6 A) (see also Snipes and Suter, 1995) . In contrast, nerve sections of adult Tr J /ϩ mice show low levels of myelin-like anti-PMP22 immunoreactivity, whereas a significant proportion of the PMP22 protein appears to accumulate in some of the Schwann cell perikarya (Fig. 6 D, arrowheads) . We interpret the myelin-like immunoreactivity as representing both myelin and cytoplasmic staining of PMP22. In longitudinal sections, the Schwann cells with cytoplasmic immunoreactive PMP22 from the Tr gesting a generalized increase in protein degradation. Particularly striking is the marked increase in LAMP1 levels in Tr J /ϩ, compared with adult normal nerves. As our morphological studies suggest (Fig. 2 F) , there is an active myelin breakdown in Tr J /ϩ nerves. The parallel decrease in structural myelin components (P0, MBP, and PMP22) and increase in lysosomal constituents were reconfirmed by reprobing the same blots with all six different antibodies (MAG, P0, PMP22, MBP, LAMP, and CatD).
To correlate the intracellular localization of PMP22, MAG, and P0 with the enhanced lysosomal activity and apparent myelin instability in Tr J /ϩ nerves, chloroquine-treated ex vivo nerve samples were analyzed (Fig. 9) . Chloroquine, a weak base, is thought to inhibit lysosomal enzyme activity by increasing the pH of the acidic vesicles leading to the accumulation of proteins that are destined for degradation (Brown et al., 1984) . After a 16 hr chloroquine treatment, we found a notable accumulation of PMP22, P0, and MBP in Tr J /ϩ nerves (Fig. 9A) . Compared with these compact myelin proteins, MAG levels were less affected. We detected only a small increase in the levels of the same proteins in chloroquine-treated normal nerves, likely reflecting general protein degradation secondary to early Wallerian degeneration during the overnight incubation period. Chloroquine sensitivity of PMP22, P0, and MBP degradation further supports increased endocytosis /autophagy in Tr J /ϩ nerves.
DISCUSSION
Recent and emerging studies reveal a variety of pathogenetic mechanisms by which mutations in myelin genes can cause hereditary myelinopathies. In humans, a large proportion of patients with CMT and hereditary neuropathy with liability to pressure palsies are caused by altered PMP22 gene dosage resulting from a duplication or deletion, respectively, of a submicroscopic portion of chromosome 17 containing the human PMP22 gene (see Suter and Snipes, 1995a) . Although controversial, the altered PMP22 gene dosage in CMT1A appears to be reflected by increased levels of PMP22 mRNA in Schwann cells (Yoshikawa, 1994) and PMP22 protein in peripheral myelin (Vallat, 1996 ; see also Hanemann, 1994) . In mouse models alone, altered dosage of normal myelin genes causing myelination defects has now been described for the major compact myelin proteins in both the CNS and PNS, namely for MBP (Shine et al., 1992) , P0 (Giese et al., 1992; Martini et al., 1995) , PLP (Nave, 1994) , and PMP22 (Adlkofer et al., 1996; Magyar et al., 1996; Sereda et al., 1996) . In addition, apparent gain of function, as well as dominant negative mutations, has been identified among this group of proteins (Warner et al., 1996) . It is within this background that we discuss the effects of the L16P mutation in the first putative transmembrane domain of the PMP22 protein in the Tr J mouse. Since the original description of the Tr and Tr J mice, these animals have been used as models of human hereditary peripheral neuropathies (Nave, 1994) . We have begun to address the cellular pathogenesis of the PMP22 myelinopathies by focusing on the Tr J neuropathy. Our studies confirmed and extended earlier morphological and immunochemical (Heath et al., 1991) findings in Tr J mice. Data indicate an increasing disparity between normal and diseased nerves in the Tr J neuropathy with advancing age, similar to the disease progression in humans with CMT1A and the Tr mouse (Ayers et al., 1976; Low, 1977) . We show that the Tr J neuropathy is manifest as a primary dysmyelination early in myelin formation. Studies on children with CMT1A also reveal heterogeneous nonprogressive slowing of nerve conduction from early childhood consistent with a dysmyelinating process with full genetic penetrance (Nicholson, 1991; Kaku et al., 1993a,b) . The Tr J and CMT1A clinical phenotypes are similar; namely, both are progressive sensorimotor neuropathies, although their pathologies and axon-myelin thickness relationships differ (Gabreels-Festen, 1995) . Thus, although there are many similarities between the Tr J neuropathy caused by a point mutation and CMT1A attributable to PMP22 duplication, there are likely to be fundamental pathogenetic similarities and differences that remain to be elucidated.
The major finding in this paper is that the endosomal / lysosomal pathways are activated in the Tr J neuropathy and that PMP22 and other myelin proteins are degraded at a high rate in Tr J /ϩ nerves. There are several cellular mechanisms by which a mutant transmembrane glycoprotein may be degraded. First, if the mutation interferes with the normal folding or oligomerization of the protein, then it is retained and degraded in the ER (Bonifacio and Lippincott-Schwartz, 1991) . A second possible pathway involves the direct transport of the glycosylated mutant protein from the trans-Golgi network to endosomal / lysosomal vesicles. This pathway has been described for the transport of lysosomal proteins via specific targeting sequences (Green et al., 1987; Kornfeld and Mellman, 1989 ), but has not yet been implicated in the elimination of mutant proteins destined for the plasma membrane. Third, the mutant protein could translocate to the plasma membrane, where its insertion may be unstable. Autophagy of the mutant protein (or abnormal membranes) would lead to degradation by the lysosomal pathway.
Based on recent in vitro studies of the Tr mutation in pmp22 (Naef et al., 1997) and several proteolipid protein mutations (Gow et al., 1994) , we had reason to expect that the nonconservative L16P mutation in PMP22 underlying the Tr J neuropathy would result in its ER retention and degradation. In these mutations, the abnormal protein is apparently recognized as defective and is retained in the ER. Degradation of misfolded or incorrectly oligomerized proteins from the ER is a commonly used pathway (Bonifacio and Lippincott-Schwartz, 1991) for ensuring the integrity of protein synthesis. As will be discussed below, we find no evidence that the effect of the Tr J mutation is manifest at the level of the ER. That not all mutations are detected by ER fail-safe mechanisms is clearly shown by studies of mutations in transmembrane proteins underlying other human diseases (for review, see Amara et al., 1992) . For example, depending on the specific mutation in the rhodopsin molecule, the mutant protein may be retained in the ER or may be transported to the plasma membrane (Sung et al., 1991) . We hypothesize that the differences observed between Tr and Tr J mice with regards to the intracellular processing of PMP22 reflect a similar pleiotropism. Alternative explanations, however, including species differences attributable to distinct genetic backgrounds and methodological differences, will need to be explored further.
Although the products of the normal and the mutated pmp22 alleles were not differentiated in heterozygous Tr J /ϩ mice, we do not believe that the mutated PMP22 in Tr J /ϩ animals is selectively eliminated by ER retention and degradation for several reasons. First, our immunohistochemical results co-localizing most of the intracellular PMP22 in Tr J /ϩ nerves with lysosomal markers, and not ER markers, argue against a mutation-specific ER retention. This histochemical localization is consistent with our inability to detect a pool of ER-and /or Golgi-resident endoH-sensitive PMP22 in Tr J /ϩ nerves, even though this pool is readily visible in normal nerves. One interpretation of this finding is that newly glycosylated PMP22 is used more rapidly in Tr J /ϩ nerves than in normal nerves, reflecting increased myelin turnover. Furthermore, simply removing the mutated PMP22 protein from the ER (assuming no other effects of the mutated protein) would lead to a 50% reduction in functional protein, which should result in the phenotype of heterozygous PMP22 knock-out (PMP22 0/ϩ ) mice. PMP22 0/ϩ mice display prominent tomacula at a young age (Adlkofer et al., 1995) . In contrast, we and others find only a few of these structures in Tr J /ϩ nerves. Moreover, homozygous pmp22 knock-out mice live past 20 weeks of age, whereas Tr J /Tr J animals die at P18, again indicating either a gain of function or a dominant-negative effect for the Tr J protein. The effects of different genetic backgrounds in these examples are unlikely to be significant, because both PMP22 0/ϩ and Tr J /ϩ mice appear to faithfully reflect their human disease counterparts, hereditary neuropathy with liability to pressure palsies (Adlkofer et al., 1995) and variant CMT1A (Valentijn et al., 1992) . Finally, ER retention and degradation of mutated PMP22 would not explain the accumulation of PMP22, MBP, and P0 in endosomes / lysosomes after chloroquine treatment.
It is difficult to distinguish from the data presented here whether there is direct transport of mutated PMP22 from the Golgi network to lysosomes, or whether the mutation leads to increased instability of myelin, without determining if the mutated PMP22 protein is incorporated into myelin. A specific shunting of trans-Golgi mutant PMP22 resulting in a 50% reduction of PMP22 is unlikely based on the observed differences between PMP22 0/ϩ and Tr J mice. Furthermore, if the mutated PMP22 is shunted directly to endosomes / lysosomes without being incorporated into myelin, it would have to be associated with other myelin proteins, perhaps as "premyelin" vesicles, to account for the increased accumulation with P0 and MBP in endosomes / lysosomes after chloroquine treatment. The possibility of an effect on "premyelin" vesicles seems particularly unlikely for MBP, a cytoplasmic protein synthesized on free polyribosomes in close proximity to myelin assembly (for review, see Campagnoni and Macklin, 1988) . Ultimately though, this putative pathway fails to explain why the leftover wild-type PMP22 and the other compact myelin proteins cannot support the formation of normal myelin over a longer period of time.
The possibility that the L16P PMP22 mutation might behave either as a dominant negative mutation by disrupting the interaction of PMP22 with itself or other myelin proteins, or as a gain of function mutation by sequestering interacting proteins or overwhelming degradation pathways during biosynthesis and processing or within the myelin membranes, cannot be readily dismissed.
The altered expression pattern and intracellular detection of P0 and MAG in Tr J /ϩ nerves may indicate an interaction of PMP22 with MAG and /or P0. These transmembrane myelin proteins carry adhesion motifs and are thought to have a role in PNS myelin formation and maintenance (for review, see Snipes and Suter, 1995) . In vivo homotypic and /or heterotypic interaction and likely multimerization of myelin proteins have been proposed but has only been documented in vitro (D'Urso et al., 1990; Sinoway et al., 1994; Jung et al., 1995) . These protein interactions may take place during intracellular trafficking, such as in the case of PLP and DM20 (Sinoway et al., 1994) and /or in the plasma membrane (D'Urso et al., 1990; Shapiro et al., 1996) . Our morphological and biochemical studies suggest that the Tr J mutation in PMP22 leads 
